You are here

Article info

Article menu
XML
Oncolytic and local immunotherapy
Original research
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

Authors

  • Casey R Ager Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Akash Boda Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Kimal Rajapakshe Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Spencer Thomas Lea Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Maria Emilia Di Francesco Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Priyamvada Jayaprakash Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Ravaen B Slay Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Brittany Morrow Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Rishika Prasad Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Meghan A Dean Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Colm R Duffy Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Cristian Coarfa Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Philip Jones Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Michael A Curran Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Michael A Curran; mcurran{at}mdanderson.org
View Full Text

Citation

Ager CR, Boda A, Rajapakshe K, et al
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege
Journal for ImmunoTherapy of Cancer 2021;9:e003246. doi: 10.1136/jitc-2021-003246

Publication history

  • Accepted July 9, 2021
  • First published August 2, 2021.
Online issue publication 
November 02, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.